spending lots on fda approval..Inflammation is at the core of many common diseases. Initial proof of concept studies on humans and animals, already undertaken by Argyll Biotechnologies; strongly suggest that its SF-1019 platform technology, with its ability to induce both an adaptive and innate human immune response, combined with its extensive anti-inflammatory and analgesic properties, amongst others, may be of benefit in the treatment of many human diseases.
SF-1019 was initially developed as an aid to wound healing and to treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). However, it is believed that SF-1019 might be of additional benefit, either in its existing form or with disease specific peptide adjustments or adaptations for treatment of some Cancers and Inflammatory Bowel Diseases. Such diseases and conditions might include Ulcerative Colitis and Crohn's Disease, Atherosclerosis which can lead to heart attack or stroke, Osteoarthritis, Chronic Obstructive Pulmonary (Lung) Disease, Rheumatoid Arthritis, Multiple Sclerosis, Diabetes and many neurodegenerative diseases such as Alzheimer's, Lou Gehrig's Disease, HIV / AIDS Psoriasis, and others with an inflammatory component attached to them.
The need to understand and develop treatments for inflammatory and infectious diseases is critical, as it is currently estimated that within the next ten years many of the antibiotics currently employed for treating bacterial infections will no longer be effective due to microbial resistance.
As part of its first stage strategy, Argyll Biotechnologies and its research partners are currently preparing a comprehensive program designed to examine the potential of SF-1019 and develop effective treatments for:
•Various cancers •Asthma and Chronic Obstructive Pulmonary Disease (COPD) •Inflammation of the heart (Myocarditis) •Lou Gehrig's Disease (motor neurone) •Type 2 Diabetes